type 2 diabetes

GLP-1 Receptor Agonists Not Ready for Acute Stroke Neuroprotection, Review Finds

by
GLP-1 Receptor Agonists Not Ready for Acute Stroke Neuroprotection, Review Finds

TL;DR: A 2026 narrative review in Journal of Central Nervous System Disease found that glucagon-like peptide-1 receptor agonists have promising stroke-prevention and animal-model evidence, but human data do not yet support routine use as an acute ischemic stroke neuroprotective treatment. Key Findings Search through January 2026: The review covered preclinical stroke models, observational studies, randomized …

Read more

GLP-1 Receptor Agonists Linked to Small Hypersomnolence Risk Increase

by
GLP-1 Receptor Agonists Linked to Small Hypersomnolence Risk Increase

TL;DR: A 2026 real-world cohort study in Journal of Diabetes & Metabolic Disorders linked GLP-1 receptor agonists, drugs targeting a glucose-related metabolic hormone pathway, to a higher hazard of new hypersomnolence, but the absolute risk increase was small. Key Findings 237,986 matched patients: The TriNetX analysis compared 118,993 GLP-1 receptor agonist users with 118,993 matched …

Read more

SMART Text Messages Improved Self-Management in Schizophrenia Metabolic Health Pilot

by
SMART Text Messages Improved Self-Management in Schizophrenia Metabolic Health Pilot

TL;DR: A 2026 uncontrolled pilot study in BJPsych Open found that SMART, a personalized text-message program for metabolic health in people with schizophrenia spectrum disorders, improved patient activation, diabetes self-management confidence, health literacy, and recovery scores over 12 weeks, while objective cardiometabolic markers did not significantly change. Key Findings SMART reached a schizophrenia-risk group: Researchers …

Read more

Antipsychotic D2 Blockade May Disturb Pancreatic Insulin Secretion

by
Antipsychotic D2 Blockade May Disturb Pancreatic Insulin Secretion

TL;DR: A 2026 systematic review and meta-analysis in Neuropsychopharmacology found that dopamine D2-like receptor activation suppressed glucose-stimulated insulin secretion (GSIS), insulin release after high glucose, in animal pancreatic cells, suggesting one peripheral route by which antipsychotic dopamine blockade can disturb glucose control beyond weight gain. Key Findings 39 eligible studies: Researchers screened 12,457 citations and …

Read more

Metformin’s Hidden Brain Mechanism: How the Hypothalamus Controls Blood Sugar

by

Metformin’s Secret Weapon: How the Brain Controls Blood Sugar TL;DR: Metformin’s glucose-lowering effect depends on a brain signaling pathway—it inhibits Rap1 in the hypothalamus, activating neurons that tell the liver to stop overproducing glucose. For decades, metformin has been the first-line drug for type 2 diabetes, working so reliably that millions take it daily. Yet …

Read more

Type 2 Diabetes vs. Depression and Anxiety: The Bidirectional Relationship

by

Diabetes and Depression Are Not Just Comorbidities—They Drive Each Other TL;DR: Diabetes and depression form a vicious cycle: high blood sugar triggers neuroinflammation and HPA axis dysfunction that cause depression, while depression sabotages blood sugar control through behavioral and metabolic pathways. Doctors have known for years that depression and type 2 diabetes often occur together. …

Read more

Type 2 Diabetes Linked to Lower Cerebral Blood Flow (CBF) in Hippocampus (2024 Study)

by

This study shows that type 2 diabetes causes decreased blood flow and changes in neural activity in specific parts of the hippocampus, which may initially compensate for cognitive decline but deteriorate with worsening diabetes. Highlights: Decreased Perfusion: Patients with type 2 diabetes have lower blood flow in the right hippocampal CA1, DG, and subiculum areas. …

Read more

Case Report: Ozempic (Semaglutide) Worsening Depression in 54-Year-Old Female (2024)

by

GLP-1 receptor agonists like semaglutide, used for managing Type 2 diabetes, may be linked to adverse mood changes, necessitating further investigation into their psychiatric effects. Highlights: GLP-1 Receptor Agonists: These medications mimic GLP-1 hormone effects, enhancing insulin secretion and reducing appetite, commonly used for Type 2 diabetes management. Mood Effects: Data on the impact of …

Read more

GLP-1 Receptor Agonists & Lower Dementia Risk in Older Adults with Diabetes (2024 Study)

by

TLDR: GLP-1 agonists were found to significantly reduce the risk of dementia in older individuals with type 2 diabetes mellitus (T2DM) compared to DPP-4 inhibitors and sulfonylureas. Highlights: A sequential trial emulation was conducted using data from Swedish national registers from 2010 to 2020, involving 88,381 participants aged 65 or older with T2DM. The incidence …

Read more

Semaglutide: The Popular GLP-1 Receptor Agonist with Many Potential Medical Uses

by

Semaglutide is emerging as a wonder drug for management of various metabolic diseases. Originally approved for type 2 diabetes, this glucagon like peptide-1 (GLP-1) receptor agonist is now showing promise for treating obesity, non-alcoholic steatohepatitis (NASH), and neurodegenerative diseases like Alzheimer’s and Parkinson’s. Let’s explore the therapeutic potential of semaglutide and how it acts as …

Read more

+ Load more